ALB and liver cancer: Forty-four (69.8%) patients were Barcelona Clinic Liver Cancer classification (BCLC) C, and the modified albumin-bilirubin (mALBI) classifications were 1 (n = 18), 2a (n = 20) and 2b (n = 25).